EGFR and thymus neoplasm: Though several signaling pathways have been explored in thymic tumors, clinical trials with EGFR, KIT, VEGF, and IGF-1R, histone deacetylase, DNA methyltransferase, tropomyosin receptor kinase A, and, cyclin-dependent kinase inhibitors documented only modest clinical responses in advanced disease[4, 5, 15].